We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Chimeric Antigen Receptor-T-Cell Therapy for B-Cell Hematological Malignancies: An Update of the Pivotal Clinical Trial Data.
- Authors
Roex, Gils; Feys, Tom; Beguin, Yves; Kerre, Tessa; Poiré, Xavier; Lewalle, Philippe; Vandenberghe, Peter; Bron, Dominique; Anguille, Sébastien
- Abstract
Chimeric antigen receptor (CAR)-T-cell therapy is an innovative form of adoptive cell therapy that has revolutionized the treatment of certain hematological malignancies, including B-cell non-Hodgkin lymphoma (NHL) and B-cell acute lymphoblastic leukemia (ALL). The treatment is currently also being studied in other B-cell neoplasms, including multiple myeloma (MM) and chronic lymphocytic leukemia (CLL). CD19 and B-cell maturation antigen (BCMA) have been the most popular target antigens for CAR-T-cell immunotherapy of these malignancies. This review will discuss the efficacy and toxicity data from the pivotal clinical studies of CD19- and BCMA-targeted CAR-T-cell therapies in relapsed/refractory B-cell malignancies (NHL, ALL, CLL) and MM, respectively.
- Subjects
HEMATOLOGIC malignancies; CHRONIC lymphocytic leukemia; CHIMERIC antigen receptors; CLINICAL trials; ANTIGENS; RITUXIMAB; T cell receptors; B cells
- Publication
Pharmaceutics, 2020, Vol 12, Issue 2, p194
- ISSN
1999-4923
- Publication type
Article
- DOI
10.3390/pharmaceutics12020194